Innovative cancer therapies: Putting costs into context

Cancer

Volumn 118, Issue 9, 2012, Pages 2367-2371

  Khayat, David ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

budgets; cancer; costs and cost analysis; new oncology products

Indexed keywords

ANTINEOPLASTIC AGENT; TRASTUZUMAB;

BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CANCER THERAPY; ECONOMIC EVALUATION; FUNDING; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DISPARITY; HEALTH SERVICE; HUMAN; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS; EUROPE; FEMALE; FRANCE; HEALTH CARE COSTS; HUMANS; NEOPLASMS; THERAPIES, INVESTIGATIONAL;

EID: 84855642344     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26496     Document Type: Review

References (42)

1. Wilking N, Jonsson B, Hogberg D,. Comparator Report on Patient Access to Cancer Drugs in Europe. Stockholm, Sweden: The Karolinska Institute; 2009. Available at:. Accessed October 24, 2010.
2. Stuckler D, Basu S, Suhrcke M, et al. The public health effect of economic crises and alternative policy responses in Europe: an empirical analysis. Lancet. 2009; 374: 315-323.
3. D'Addario G, Fruh M, Reck M, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v116-v119.
4. Cardoso F, Senkus-Konefka E, Fallowfield L, et al. Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v15-v19.
5. Dreyling M,. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 (suppl 5): v181-v183.
6. Van CE, Nordlinger B, Cervantes A,. Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. Ann Oncol. 2010; 21 (suppl 5): v93-v97.
7. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007; 18: 581-592.
8. Verdecchia A, Francisci S, Brenner H, et al. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007; 8: 784-796.
9. Guerin S, Doyon F, Hill C,. [The frequency of cancer in France in 2006, mortality trends since 1950, incidence trends since 1980 and analysis of the discrepancies between these trends]. Bull Cancer. 2009; 96: 51-57.
10. French National Cancer Institute (INCa). [Economic Analysis of the Cost of Cancer in France-Impact of the Quality of Life, Prevention, Screening, Care, and Research.] Boulogne-Billancourt, France: INCa; 2007.
11. Interministerial Mission for the Fight Against Cancer. Plan Cancer 2003-2007. Paris, France: Ministry of Health, Ministry of Research; 2003. Available at:. [Accessed July 11, 2011.]
12. Kaplan W, Laing R,. Priority Medicines for Europe and the World. HO/EDM/PAR/2004.7. Geneva, Switzerland: World Health Organization, Department of Essential Drugs and Medicines Policy; 2004. Available at:. [Accessed July 8, 2011].
13. Jonsson B, Wilking N,. A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007; 18 (suppl 3): iii1-iii77.
14. Lidgren M, Wilking N, Jonsson B,. Cost of breast cancer in Sweden in 2002. Eur J Health Econ. 2007; 8: 5-15.
15. Vallier N, Weill A, Salanave B, et al. Cost of thirty long-term diseases for beneficiaries of the French general health insurance scheme in 2004 [article in French]. Prat Organ Soins. 2006; 37: 257-283.
16. Civan A, Koksal B,. The effect of newer drugs on health spending: do they really increase the costs? Health Econ. 2010; 19: 581-595.
17. Campbell JD, Ramsey SD,. The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics. 2009; 27: 199-209.
18. Garrison LP Jr, Veenstra DL,. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health. 2009; 12: 1118-1123.
19. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355: 2542-2550.
20. Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010; 5: 1416-1423.
21. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344: 783-792.
22. Perez EA, Romond EH, Suman VJ, et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. 2007 ASCO Annual Meeting Proceedings [abstract]. J Clin Oncol. 2007; 25 (18S). Abstract 512.
23. Welch S, Spithoff K, Rumble RB, et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010; 21: 1152-1162.
24. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108: 3295-3301.
25. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008; 26: 4579-4586.
26. Hallek M, Fingerle-Rowson G, Fink AF, et al. First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an international group of investigators and the German CLL Study Group. 2009 ASH Annual Meeting Abstracts [abstract]. Blood. 2009; 114. Abstract 535.
27. Herold M, Schulze A, Niederwieser D, et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO 19). J Cancer Res Clin Oncol. 2006; 132: 105-112.
28. von Plessen C, Strand TE, Wentzel-Larsen T, et al. Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study. Thorax. 2008; 63: 866-871.
29. Brenner H, Gondos A, Pulte D,. Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level. Haematologica. 2008; 93: 1544-1549.
30. Brenner H, Gondos A, Pulte D,. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008; 111: 2521-2526.
31. Molina A,. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med. 2008; 59: 237-250.
32. Pulte D, Gondos A, Brenner H,. Ongoing improvement in outcomes for patients diagnosed as having non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med. 2008; 168: 469-476.
33. Pulte D, Gondos A, Brenner H,. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009; 113: 1408-1411.
34. Brenner H, Gondos A, Pulte D,. Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010. Oncologist. 2009; 14: 806-813.
35. Brenner H, Gondos A, Pulte D,. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica. 2009; 94: 270-275.
36. Brenner H, Gondos A, Pulte D,. Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood. 2008; 111: 2977-2983.
37. Pulte D, Gondos A, Brenner H,. Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010. Ann Oncol. 2010; 21: 335-341.
38. Coleman MP,. Not credible: a subversion of science by the pharmaceutical industry. Ann Oncol. 2007; 18: 1433-1435.
39. Willyard C,. Karolinska Institute under fire for controversial cancer report. Nat Med. 2007; 13: 1124-1124.
40. Fenina A, Geffroy Y,. [National Health Accounts 2004. No. 85]. Paris, France: Ministry of Health; 2005: Available at:. [Accessed August 23, 2011.]
41. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353: 1673-1684.
42. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353: 1659-1672.